Eidos Therapeutics, Inc. Common Stock
EIDX
EIDX was delisted on the 25th of January, 2021.
63 hedge funds and large institutions have $334M invested in Eidos Therapeutics, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 22 increasing their positions, 11 reducing their positions, and 11 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 11
84% more capital invested
Capital invested by funds: $182M → $334M (+$152M)
27% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 11
5% more funds holding
Funds holding: 60 → 63 (+3)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$7.45M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$4.62M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$4.49M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
+$2.97M |
| 5 |
State Street
Boston,
Massachusetts
|
+$2.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$5.94M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$716K |
| 3 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
-$660K |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$384K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$367K |
EIDX Hedge Fund Activity: Q1 2019 in Review
63 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Eidos Therapeutics, Inc. Common Stock (EIDX) for Q1 2019, worth a combined $334M — up 84% from $182M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new EIDX positions and 11 closed out — a net gain of 3 holders — while 22 added to existing stakes and 11 trimmed.
The largest buyer was BlackRock, adding an estimated $7.45M. The largest seller was Foresite Capital Management IV, exiting entirely with an estimated $5.94M sold.
- 63 institutional investors held Eidos Therapeutics, Inc. Common Stock (EIDX) as of Q1 2019, up from 60 in Q4 2018.
- Funds reported $334M of Eidos Therapeutics, Inc. Common Stock stock for Q1 2019, up 84% quarter-over-quarter.
- 14 funds opened new Eidos Therapeutics, Inc. Common Stock positions in Q1 2019 and 11 closed out, a net change of +3 holders.
- The largest Eidos Therapeutics, Inc. Common Stock buyer in Q1 2019 was BlackRock, an estimated $7.45M added.
- The largest Eidos Therapeutics, Inc. Common Stock seller in Q1 2019 was Foresite Capital Management IV, an estimated $5.94M sold.
Based on aggregated 13F filings for Q1 2019.